Inhibrx Biosciences, Inc.
NASDAQ:INBXBiotechnology
-$2.58 today
- Market cap
- $1.02B
- Beta
- 3.32
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$8.35
Volume 0.29M
Average 0.43M
INBX Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Inhibrx Biosciences, Inc.NASDAQ: INBX
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns negative
Q1 FY2026 accounts receivables was -$9K, compared with $206K a year earlier. Trailing-twelve-month accounts receivables was $28K. Over 3 fiscal years it compounded at +23.2% a year.
Context
- Accounts receivables amounted to 18.7% of revenue in FY2025, down 171.8 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near -$9K or moves back toward the trailing-twelve-month quarterly average of $7K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 243K USD
- Year-over-year change
- -36.2%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 243K | -36.2% |
| FY2024 | 2024-12-31 | 381K | +173.1% |
| FY2023 | 2023-12-31 | (521K) | -500.8% |
| FY2022 | 2022-12-31 | 130K | +177.8% |
| FY2021 | 2021-12-31 | (167K) | — |
Accounts Receivables vs competitors
How INBX compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -97.6% is the 5th highest of 6, against a peer median of +207.1%.
- Accounts receivables amounts to 2.2% of revenue for INBX, versus a peer median of 75.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $35M USD | +401.4% | — | 161.9% | |
| LTM Mar 2026 | €1.5M EUR | +138.9% | -18.5% | 4.0% | |
| LTM Mar 2026 | $1.38M USD | +207.1% | — | 75.4% | |
GENBGenerate Biomedicines, Inc. | FY2025 | $308K USD | +244.6% | — | 1.0% |
| LTM Sep 2026 | $265K USD | -134.8% | +95.9% | 236.6% | |
| LTM Mar 2026 | $28K USD | -97.6% | +23.2% | 2.2% | |
TECXTectonic Therapeutic, Inc. | LTM Mar 2026 | $0 USD | — | — | — |
| Peer median (excluding INBX) | — | +207.1% | +38.7% | 75.4% | |
Competitors are the stored peer set for INBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (81.77M) | (145.23M) | (239.73M) | 1.69B | (140.06M) |
| Depreciation & Amortization | 1.2M | 1.23M | 1.19M | 2.29M | 2.48M |
| Deferred Income Tax | (9K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 15.05M | 20.45M | 24.85M | 58.52M | 11.14M |
| Change in Working Capital | (17.52M) | 3.16M | 15.35M | 52.05M | (7.61M) |
| Accounts Receivables | (167K) | 130K | (521K) | 381K | 243K |
| Inventory | (11.03M) | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.64M) | (705K) | 2.11M | 17.9M | (3.3M) |
| Other Working Capital | (1.67M) | 3.74M | 13.76M | 33.77M | (4.56M) |
| Other Non-Cash Items | 2.73M | 5.09M | 5.03M | (1.99B) | 4.25M |
| Operating Cash Flow | (80.32M) | (115.3M) | (193.31M) | (194.41M) | (129.79M) |
| Capital Expenditures | (864K) | (686K) | (4.59M) | (2.6M) | (31K) |
| Acquisitions (Net) | 55K | 0 | 0 | 0 | 3K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (809K) | (686K) | (4.59M) | (2.6M) | (28K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 99.84M |
| Common Stock Issued | 40.2M | 129.74M | 201.96M | 71.68M | 1.61M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 83.77M | 128.81M | 0 | 0 | 0 |
| Financing Cash Flow | 83.77M | 258.55M | 201.96M | 71.68M | 101.45M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 2.64M | 142.56M | 4.06M | (125.33M) | (28.38M) |
| Free Cash Flow | (81.19M) | (115.99M) | (197.9M) | (197.01M) | (129.83M) |
Inhibrx Biosciences, Inc.
NASDAQ:INBX
Intrinsic Alpha fair value
Locked
Current Price
$69.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.